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cues for cell and tissue regeneration, presumably by mimick-
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NANOFILAMENT SCAFFOLD FOR TISSUE 
REGENERATION 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims benefit of U.S. Provisional Appli-
cation No. 60/659,218, filed Mar. 7, 2005. That application is 
incorporated herein by reference in its entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with U.S. govermnent support 
under Contract No. EEC-9731643 awarded by the National 
Science Foundation and under Contract No. R01NS044409-
02 awarded by the National Institutes of Health. The U.S. 
govermnent has certain rights in the invention. 
BACKGROUND OF THE INVENTION 
This invention is generally in the field of tissue engineer-
ing, and more particularly pertains to synthetic scaffold mate-
rials and methods useful in directing tissue growth in vivo or 
ex VIVO. 
Severe traumatic injury or invasive surgical procedures on 
a peripheral nerve can result in a gap between two nerve 
stumps. The clinical "gold standard" for bridging peripheral 
nerve gaps is the use of auto grafts, typically, the sensory sural 
nerve. However, the use of autografts is limited by the inad-
equate availability of nerves to use in the autograft (IJkema-
Paassen, et al., Biamaterials 25:1583-92 (2004)), the lack of 
co-adaptation between the injured nerve and the nerve graft 
due to size/length/modality mismatch (Nichols, et al., Exp. 
Neural. 190:347-55 (2004)), and functional loss at the donor 
sites (Bini, et al., J. Biamed. Mater. Res A 68:286-95 (2004)). 
Moreover, complications at the donor site such as numbness, 
hyperesthesia, or formation of painful neuroma also have to 
be addressed (Itoh, et al., Biamaterials 23:4475-81 (2002); 
Matsuyama, et al., Neural. Med. Chir. (Tokyo) 40:187-99 
(2000)). Therefore, it is imperative that alternative 
approaches that are ready-to-use, pre-customized for reduc-
ing the mismatch, and suitable for both sensory and motor 
nerve regeneration are developed. 
Many research and development efforts are focused on 
manipulating cell growth, proliferation, and differentiation to 
repair or replace damaged tissue structures in the body, or to 
grow tissues and organs. One approach is the use of engi-
neered tissue scaffolds. 
Tubular nerve conduits have been used clinically for repair-
ing peripheral nerve injury (Taras, et al., J. Hand Ther. 
18:191-97 (2005)). These nerve conduits, which are made of 
non-porous silicone or porous natural/synthetic polymers, 
bridge the injured nerve stumps and help form a fibrin cable 
which provides a substrate for the ingrowth of Schwarm cells 
and other cells such as fibroblasts. The infiltrating Schwarm 
cells reorganize to create longitudinally oriented bands of 
Bungner, which serve as a guiding substrate and a source of 
neurotrophic factors to foster axonal regrowth (Bungner, 
1891; Ide, Neurasci Res. 25: 101-21 (1996)). However, these 
approaches are limited in their ability to enable regeneration 
across long nerve gaps, and have been unsuccessful in pro-
moting regeneration across gaps longer than 15 mm in 
rodents. Failure of nerve regeneration across long gaps, i.e., 
those greater than 15 mm, seems to be the result of a lack of 
2 
the formation of an initial fibrin cable, which is necessary for 
the formation of the bands ofBungner (Lundborg, et al., Exp. 
Neura. 76:361-75 (1982)). 
Conventional tissue engineering scaffolds are isotropic and 
provide no directional cues to promote directional cell and 
tissue growth and regeneration, and require the addition of 
exogenously delivered neurotrophic factors to increase the 
intrinsic growth capacity of injured axons. Accordingly, there 
exists a need to develop a scaffold that promotes directional 
10 
cell and tissue growth and regeneration across long nerve 
gaps. More generally, there exists a need to develop an engi-
neered scaffold that promotes directional cell and tissue 
growth and regeneration for use in a variety of applications, 
15 such as cartilage, bone, neural, and cardiovascular tissue 
engineering. 
20 
SUMMARY OF THE INVENTION 
An improved scaffold for tissue regeneration has been 
developed. In one aspect, a scaffold is provided that includes 
a structure comprising a plurality of uniaxially oriented 
nanofibers made of at least one synthetic polymer. In a pre-
ferred embodiment, at least 75% of the nanofibers are ori-
25 ented within 20 degrees of the uniaxial orientation. In one 
embodiment, the nanofibers have a diameter between about 
400 nm and about 1000 nm. In a preferred embodiment, the 
tissue scaffold is implantable scaffold and the structure com-
prises two or more stacked layers of the uniaxially oriented 
30 nanofibers, the layers being oriented such that the nanofiber 
orientation of among the layers is substantially identical. In 
one embodiment, the structure further includes at least one 
spacer between layers of uniaxially oriented nano fibers in the 
stacked layers. In one case, the spacer has a thickness between 
35 50 and 250 µm. The space may include a hydrogel, polyeth-
ylene glycol, agarose, alginate, polyvinyl alcohol, collagen, 
Matrigel, chitosan, gelatin, or a combination thereof. For 
example, the structure may include alternating layers of ori-
ented nanofibers and layers ofhydrogel. In one embodiment, 
40 the implantable scaffold further includes a tubular conduit in 
which the structure is disposed. 
The synthetic polymer of the implantable scaffold may be 
biodegradable or non-biodegradable, or a combination (e.g., 
mixture) of these types of polymers. Examples of suitable 
45 biodegradable polymers include poly( caprolactone ), poly 
(lactic-co-glycolic acid), poly(lactic acid), or a combination 
thereof. An example of a suitable non-biodegradable polymer 
is poly(acrylonitrile ). 
In one embodiment, the implantable scaffold further 
50 includes at least one bioactive agent. In one embodiment, the 
bioactive agent is a growth factor or differentiation factor. For 
instance, a scaffold for nerve regeneration may include a 
neurotrophic factor. The implantable scaffold may include a 
plurality oflipid microtubules or nanoparticles disperse on or 
55 among the nanofibers for controlled release of the bioactive 
agent, or the bioactive agent may, along with the at least one 
synthetic polymer, form the nanofibers themselves. 
In one particular embodiment, a scaffold for tissue regen-
eration is provided that include (i) at least two layers which 
60 include a plurality ofuniaxially oriented, polymeric nanofi-
bers, wherein at least 75% of the nanofibers are oriented 
within 20 degrees of the uniaxial orientation and wherein the 
layers are stacked and oriented such that the nanofiber orien-
tation of among the layers is substantially identical; (ii) one or 
65 more spacers in the stacked layers, between the at least two 
layers ofuniaxially oriented nanofibers, wherein the spacers 
comprise a hydrogel. 
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In another aspect, a method is provided for fabricating an 
implantable scaffold for tissue regeneration, wherein the 
method includes the steps of (i) electro spinning a polymer to 
form two or more films of uniaxially oriented nano fibers; and 
(ii) stacking the two or more uniaxially oriented nanofiber 
films together to form an oriented, three-dimensional scaf-
fold. This method may further include interposing layers of at 
least one hydrogel in between the films of uniaxially oriented 
nanofibers, and/or disposing the oriented, three-dimensional 
scaffold inside a tubular conduit with the nanofiber orienta-
tion substantially aligned in the direction of the axis of the 
conduit. 
In yet another aspect, a method is provided for tissue regen-
eration that includes the step ofimplanting one of the scaffold 
devices described above into a patient at a site in need of 
tissue regeneration. In a preferred embodiment, the site is 
between two ends of a nerve in need of regeneration. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG.1 is a perspective view ofa schematic of one embodi-
ment of a tissue scaffold with layers of uniaxially oriented 
nanofibers alternating with layers ofhydrogel. 
FIG. 2 is a photograph showing different perspectives of 
one embodiment of an implantable tissue scaffold with layers 
of uniaxially oriented nanofibers disposed in a tubular con-
duit. 
FIG. 3 is schematic showing one embodiment of an elec-
trospinning process for making uniaxially aligned nanofiber 
films. 
FIG. 4 is a schematic showing one embodiment of a pro-
cess for assembling an implantable scaffold that includes 
stacks ofuniaxially aligned nanofiber films. 
FIGS. SA-B are scanning electron micrograph images of 
one embodiment of the uniaxially aligned nanofibers. FIG. 
SB shows the nanofibers magnified (scale bar=! µm). 
FIG. 6 is a graph illustrating the distribution of nanofiber 
alignment in one example. More than 75% of all nanofibers 
fall within 20 degrees of the uniaxial orientation. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
An improved scaffold for tissue regeneration has been 
developed that can match the performance of autografts. The 
scaffold guides cell migration in vitro or in vivo. It can act as 
a bridging and guidance substrate. It was advantageously 
discovered that highly aligned fibers promote better growth, 
and that a gap between layers of fibers further improved the 
scaffold's performance. The scaffold beneficially provides 
directional cues for cell and tissue regeneration, presumably 
by mimicking the natural strategy using filamentous struc-
tures during development and regeneration. In the specific 
case of peripheral nerve regeneration, it is believed that the 
implantable scaffold of oriented nano fibers described herein 
aids or substitutes for the fibrin cable/bridge, as well as pro-
vides a guide for invasion of growth-promoting Schwarm 
cells into the scaffold. A further advantage is that the perfor-
mance of the oriented nanofiber scaffold is such that no exog-
enous trophic/ECM factors may be required to facilitate 
regeneration across a long nerve gap. That is, the oriented 
nanofibers guide endogenous supportive cell migration into 
the injury site, positively influencing regeneration across 
gaps that otherwise would not regenerate. 
Advantageously, the present nanofiber scaffolds are rela-
tively easy to fabricate, handle, store, and sterilize compared 
to obtaining autografts. Furthermore, they can be made only 
4 
of synthetic polymer, and avoid complications associated 
with the use of proteins or cells. In addition, they can be 
pre-customized (e.g., diameter or length) for different types 
of nerve injury, and are suitable for sensory, motor and mixed 
nerve repair. Moreover, unlike conventional tubular conduits, 
the present nanofiber scaffolds are less dependent on the 
formation of an initial fibrin cable between proximal and 
distal nerve stump. 
In one aspect, the implantable scaffold includes an aniso-
10 tropic three-dimensional structure which comprises a plural-
ity of uniaxially oriented nanofibers made of at least one 
synthetic polymer. 
As used herein, the terms "nanofiber" refers to a fiber, 
strand, fibril, or threadlike structure having a diameter from 
15 about 40 nm to about 1500 nm. As used herein, the term 
"nanofilament" is synonymous with "nanofiber." In a pre-
ferred embodiment, the nanofibers have a diameter from 
about 200 nm to about 1000 nm, more preferably from about 
400 nm to about 1000 nm. In one case, the nanofibers have a 
20 diameter between 500 and 800 nm. 
As used herein, the term "uniaxial orientation" refers to a 
collection of nano fibers where greaterthan 50% of the nano fi-
bers are oriented within 40° of an axis, i.e., ±20° of the axis. 
Importantly, the nanofibers are oriented in the structure over 
25 several millimeters in length, e.g., between 2 and 100 mm. In 
a preferred embodiment, at least 60%, more preferably at 
least 75%, and still more preferably at least 85%, of the 
nanofibers are within 20 degrees of the uniaxial orientation. 
As used herein, the term "implantable scaffold" means that 
30 the scaffold is suitable for use in vivo, i.e., by implantation 
into a patient in need of tissue regeneration, such as at an 
injury (or disease) site, to heal neural, cartilage, bone, cardio-
vascular and/or other tissues. In a preferred embodiment, the 
scaffold is used in the regeneration of tissues of the peripheral 
35 nervous system or the central nervous system. For example, 
the implantable scaffold can be implanted into an injured 
sciatic or cavernous nerve, or into a spinal cord or brain site. 
The term "patient" generally refers to humans or other mam-
mals. 
40 The nanofibers are formed from at least one polymer, 
which preferably is a synthetic polymer. In a preferred 
embodiment, the polymer is a biocompatible, thermoplastic 
polymer known in the art. In one embodiment, the polymer is 
a polyester or polyamide suitable for use in in vivo applica-
45 tions in humans. The polymer can be biodegradable or non-
biodegradable, or may include a mixture of biodegradable 
and non-biodegradable polymers. 
Representative examples of synthetic polymers include 
poly(hydroxy acids) such as poly(lactic acid), poly(glycolic 
50 acid), and poly(lactic acid-co-glycolic acid), poly(lactide), 
poly(glycolide ), poly(lactide-co-glycolide ), polyanliydrides, 
polyorthoesters, polyamides, polyalkylenes such as polyeth-
ylene and polypropylene, polyalkylene glycols such as poly 
(ethylene glycol), polyalkylene oxides such as poly( ethylene 
55 oxide), polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, 
polyvinylpyrrolidone, poly( vinyl alcohols), poly(butyric 
acid), poly(valeric acid), and poly(lactide-co-caprolactone ), 
copolymers and blends thereof. As used herein, "derivatives" 
include polymers having substitutions, additions of chemical 
60 groups, for example, alkyl, alkylene, hydroxylations, oxida-
tions, and other modifications routinely made by those skilled 
in the art. Examples of preferred biodegradable polymers 
include polymers of hydroxy acids such as lactic acid and 
glycolic acid, and copolymers with polyethylene glycol 
65 (PEG), polyanhydrides, poly( ortho )esters, poly(butyric 
acid), poly(valeric acid), poly(lactide-co-caprolactone ), 
blends and copolymers thereof. In a preferred embodiment, 
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the biodegradable polymer nano fibers includes a poly( capro-
lactone ), a poly(lactic-co-glycolic acid), or a combination 
thereof. 
In another embodiment, the non-biodegradable polymer 
nanofibers includes a poly(acrylonitrile). Non-degradable 
polymers may be selected for applications where structural 
support from the scaffold is necessary or where elements such 
as electrodes or microfluidics are incorporated into the scaf-
fold. 
6 
may be a polysulfone. The secondary structure may be sub-
stantially flexible or rigid, depending upon its particular per-
formance needs. 
In another embodiment, the nano fibers are formed from at 
least one natural polymer. Examples of suitable natural poly-
mers include proteins such as albumin, collagen, gelatin, 
Matrigel, Fibrin, polypeptide or self-assembling peptide 
based hydrogels, and prolamines, for example, zein, and 
polysaccharides such as alginate, agarose, cellulose and poly-
hydroxyalkanoates, for example, polyhydroxybutyrate. 
The nanofibers may be made by essentially any technique 
known in the art. In a preferred embodiment, the nanofibers 
are made using an electrospinning technique, which is well 
known in the art. See FIG. 3. Essentially any biocompatible 
polymer that is amenable to electro spinning may be used. The 
electrospinning equipment may include a rotating drum or 
10 
other adaptation at the collector end to generate fibers ori-
ented in the millimeter range. 
In one embodiment, the implantable scaffold further 
includes one or more bioactive agents, which may be pre-
In one embodiment, the structure of the implantable scaf-
fold includes multiple, stacked layers, i.e., films, of the 
uniaxially oriented nanofibers. In one embodiment, each 
layer is about 10 µm thick. Thicker or thinner layers may also 
be used; however, the thickness typically is selected to be one 
capable of handling and manipulation to stack or otherwise 
assemble a 3-D scaffold. For example, the film thickness may 
enable manual handling, such as to facilitate separation from 
a (temporary) substrate on which the nanofibers are electro-
spun. Preferably, each layer is oriented such that the nano fiber 
orientation in the stack is essentially the same. That is, the 
axial direction of all layers is pointing in substantially the 
same direction. 
15 sented or released to enhance tissue regeneration. As used 
herein, the term "bioactive agent" refers a molecule that 
exerts an effect on a cell or tissue. Representative examples of 
types ofbioactive agents include therapeutics, vitamins, elec-
trolytes, amino acids, peptides, polypeptides, proteins, car-
20 bohydrates, lipids, polysaccharides, nucleic acids, nucle-
otides, polynucleotides, glycoproteins, lipoproteins, 
glycolipids, glycosaminoglycans, proteoglycans, growth fac-
tors, differentiation factors, hormones, neurotransmitters, 
prostaglandins, immunoglobulins, cytokines, and antigens. 
25 Various combination of these molecules can be used. 
Examples of cytokines include macrophage derived chemok-
ines, macrophage inflammatory proteins, interleukins, tumor 
necrosis factors. Examples of proteins include fibrous pro-
teins (e.g., collagen, elastin) and adhesion proteins (e.g., 
Optionally, the stacked structure includes a spacer between 
some or all of the layers ofuniaxially oriented nano fibers. The 
spacer can provide sufficient openings to permit cells to infil-
trate the scaffold and attach to the oriented nanofibers. The 
spacer may be water soluble or water insoluble, porous or 
non-porous, preferably is biocompatible, and may be bio-
erodible/biodegradable. The spacer may have a thickness 
between about 25 and about 800 µm. In a preferred embodi-
ment, each spacer layer in the stack has a thickness of about 
30 actin, fibrin, fibrinogen, fibronectin, vitronectin, laminin, 
cadherins, selectins, intracellular adhesion molecules, and 
integrins). In various cases, the bioactive agent may be 
selected from fibronectin, laminin, thrombospondin, tenascin 
C, leptin, leukemia inhibitory factors, RGD peptides, anti-
35 TNFs, endostatin, angiostatin, thrombospondin, osteogenic 
protein-I, bone morphogenic proteins, osteonectin, 
somatomedin-like peptide, osteocalcin, interferons, and 
interleukins. 
50 to about 250 µm. In a preferred embodiment, the spacer 40 
includes a hydrogel, such as a thermo-reversible (i.e., tem-
perature responsive) hydro gel. In one embodiment, the struc-
ture consists of alternating layers of oriented nanofibers and 
layers ofa hydrogel orother spacer. See FIG. 1. The hydrogel, 
for instance, may be an agarose hydrogel or other hydrogel 45 
known in the art. In other embodiments, the spacer material 
may be another gel or gel-like material, such as polyethylene 
glycol, agarose, alginate, polyvinyl alcohol, collagen, Matri-
gel, chitosan, gelatin, or combination thereof. 
In an alternative embodiment, the uniaxially aligned 50 
nano fibers are provided in the structure in a form other than a 
plurality of layers. For example, the aligned nanofibers may 
be distributed evenly spaced throughout the three-dimen-
sional structure. In one embodiment, the structure is the result 
of rolling one layer, i.e., a film, of aligned nanofibers in on 55 
itself to form a spiral roll. 
The nanofibers structure optionally may be disposed in a 
secondary structure for containing, positioning, or securing 
the uniaxially oriented nano fiber structure, and/or for further 
directing or limiting tissue growth. For example, the second- 60 
ary structure may be a tubular conduit, in which the nanofiber/ 
spacer structure can be contained and through which a nerve 
tissue bridge may be grown between two nerve stumps. See 
FIG. 2. This structure preferably is also made of a biocom-
patible polymer, preferably one suitable for use in vivo. The 65 
polymer may be biodegradable or non-biodegradable, or a 
mixture thereof. In one embodiment, the secondary structure 
In a preferred embodiment, the bioactive agent includes a 
growth factor, differentiation factor, or a combination thereof. 
As used herein, the term "growth factor" refers to a bioactive 
agent that promotes the proliferation of a cell or tissue. Rep-
resentative examples of growth factors that may be useful 
include transforming growth factor-a (TGF-a), transforming 
growth factor-~ (TGF-~), platelet-derived growth factors 
(PDGF), fibroblast growth factors (FGF), nerve growth fac-
tors (NGF) including NGF 2.5s, NGF 7 .Os and beta NGF and 
neurotrophins, brain derived neurotrophic factor, cartilage 
derived factor, bone growth factors (BGF), basic fibroblast 
growth factor, insulin-like growth factor (IGF), vascular 
endothelial growth factor (VEGF), EG-VEGF, VEGF-related 
protein, Bv8, VEGF-E, granulocyte colony stimulating factor 
(G-CSF), insulin like growth factor (IGF) I and II, hepatocyte 
growth factor, glial neurotrophic growth factor (GDNF), stem 
cell factor (SCF), keratinocyte growth factor (KGF), trans-
forming growth factors (TGF), (e.g., TGFs a,~' ~1, ~2, and 
~3 ), any of the bone morphogenic proteins, skeletal growth 
factor, bone matrix derived growth factors, and bone derived 
growth factors and mixtures thereof. As used herein the term 
"differentiation factor" refers to a bioactive agent that pro-
motes the differentiation of cells. Representative examples 
include neurotrophins, colony stimulating factors (CSF), and 
transforming growth factors. Some growth factors may also 
promote differentiation of a cell or tissue. Some differentia-
tion factors also may promote the growth of a cell or tissue. 
For example, TGF may promote growth and/or differentia-
tion of cells. 
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The bioactive agent may be incorporated into the scaffold 
in a variety of different ways. In a preferred embodiment, the 
bioactive agent is located and/or formulated for controlled 
release to affect the cells or tissues in or around the oriented 
nanofiber structures. For instance, it may be dispersed in a 
controlled release matrix material. In one embodiment, the 
bioactive agent is provided in lipid microtubules or nanopar-
ticles selected to modulate the release kinetics of the bioactive 
agent. Such particles may be dispersed among the nano fibers, 
10 or provided in or on one or more layers in the scaffold struc-
ture. In another embodiment, the bioactive agent is actually 
integrated into, forms part of, the nano fibers themselves. This 
may be done, for example, by adding the bioactive agent to a 
polymer solution prior to electro spinning the solution to form 
the orientednanofibers. Release of the bioactive agent may be 15 
controlled, at least in part, by selection of the type and 
amounts ofbioerodible or biodegradable matrix materials in 
the nanoparticles or nanofibers. 
In one particular embodiment, the scaffold for tissue regen-
eration includes at least two layers which comprise a plurality 20 
of uniaxially oriented, polymeric nanofibers, wherein at least 
75% of the nanofibers are oriented within 20 degrees of the 
uniaxial orientation and wherein the layers are stacked and 
oriented such that the nanofiber orientation of among the 
layers is substantially identical; one or more spacers in the 25 
stacked layers, between the at least two layers of uniaxially 
oriented nanofibers, wherein the spacers comprise a hydro-
gel. 
In another aspect, a method is provided for fabricating an 
implantable scaffold for tissue regeneration, wherein the 30 
method includes the steps of electro spinning a polymer (solu-
tion) to form two or more films of uniaxially oriented nano fi-
bers, and stacking the two or more uniaxially oriented nano fi-
ber films together to form an oriented, three-dimensional 
scaffold. In one embodiment, the method further includes 35 
interposing layers of at least one hydrogel or other spacer 
material in between the films of uniaxially oriented nanofi-
bers. In still another embodiment, the method further includes 
disposing the oriented, three-dimensional scaffold inside a 
tubular conduit with the nanofiber orientation substantially 40 
aligned in the direction of the axis of the conduit. 
The tissue regeneration scaffolds described herein mimic 
the strategy used by collagen and other fibrillar structures to 
guide cell migration or tissue development and regeneration 
in a direction-sensitive manner. In one embodiment, a method 45 
of tissue regeneration is provided that includes the step of 
implanting into a patient an implantable scaffold as described 
above. In one particular embodiment, the site of implantation 
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cartilage, bone, neural, and cardiovascular tissues. In addi-
tion, the oriented nanofiber scaffolds may have other in vivo 
and ex vivo uses including wound repair, growth of artificial 
skin, veins, arteries, tendons, ligaments, cartilage, heart 
valves, organ culture, treatment of bums, and bone grafts. 
As used herein, the terms "comprise," "comprising," 
"include," and "including" are intended to be open, non-
limiting terms, unless the contrary is expressly indicated. 
The present invention may be further understood with ref-
erence to the following non-limiting examples. 
EXAMPLE 1 
Method of Making Oriented Nanofiber Films by 
Electro spinning 
Uniaxially oriented nanofiber films were fabricated by 
electro spinning poly( a cry lonitrile-co-methy la cry late, ran-
dom copolymer, 4 mole percent of methacry late) (PAN-MA) 
on a high speed rotating metal drum.An 18% (w/v) PAN-MA 
solution was prepared in an organic solvent, N,N-Dimethyl 
Formamide (DMF) at 60° C. The polymer solution was 
loaded into a 10 mL syringe and delivered at a constant flow 
rate (1 mL/hour) to a 21 gauge metal needle connected to a 
high voltage power supply. Upon applying a high voltage 
power supply of about 13 kV to about 18 kV, a fine jet of 
polymer solution was ejected from the needle and deposited 
on a thick aluminum foil wrapped around the high speed 
rotating metal drum. The foil carrying the aligned electrospun 
nano fiber film was then removed and stored at room tempera-
ture. The nanofiber film was approximately 10 µm thick and 
composed of nanofibers with diameters in the range of about 
400 nm to about 600 nm. See FIGS. SA-B. The alignment and 
morphology of the nanofibers were examined using scanning 
electron microscopy (S-800 SEM, Hitachi) and quantified 
with Image-Pro software (MediaCybemetics). FIG. 6 is a 
graph which illustrates the distribution of nanofiber align-
ment. More than 7 5% of all nano fibers fall within 20 degrees 
of the uniaxial orientation. 
EXAMPLE2 
Three-Dimensional Oriented Nanofiber Scaffold 
An oriented, 3-D nanofiber scaffold was created by stack-
ing the uniaxially oriented nano fiber films made as described 
in Example 1. A total of 15 nanofiber films were cut into 17 
mmxl mm pieces, removed from the aluminum foil, and 
stacked so that the orientation of the nanofibers aligned with 
the axis of regeneration within two halves of a longitudinally 
split polysulfone nerve conduit (Koch Membrane Systems, 
50,000 MW cutoff-19 mm long, 1.5 mm inner diameter). 
The longitudinal half-cut was closed and sealed using UV 
light curing adhesive. See FIG. 4. The nanofiber scaffold was 
sterilized by soaking it in a 70% ethanol solution for 30 
is between two nerve stumps in a peripheral nerve. The 
uniaxially oriented nanofibers of the scaffold promote nerve 50 
regeneration by promoting and supporting directional glial 
and nerve infiltration of the scaffold. Thus, the scaffold can be 
applied to guide the migration of endogenous or transplanted 
cells and tissues, including tissues of the peripheral and cen-
tral nervous system. 
The oriented nanofiber structures and methods described 
herein can be adapted to a variety of tissue regeneration 
applications, where guided invasion/migration of endog-
enous or transplanted cells is desired. Each tissue may require 
different densities of nano fibers for a given volume of scaf- 60 
fold for optimal performance. These parameters could be 
routinely determined for various tissues. The ability of the 
oriented nanofiber structures to guide cell migration/process 
extension also may be useful in seeding of tissue engineering 
constructs if nanofibers are embedded with/within other iso- 65 
tropic scaffolds. It is envisioned that the oriented nanofiber 
structures and methods can be applied to the regeneration of 
55 minutes and washing it three times with sterilized deionized 
water. The nanofiber scaffold was stored in sterilized PBS 
until implantation. FIG. 2 shows representative photograph of 
a single nanofiber film, stacked films, and a three-dimen-
sional nanofiber scaffold. 
EXAMPLE3 
In Vivo Nerve Tissue Growth Using Oriented, 3-D 
Nanofiber Scaffold 
The nano fiber scaffolds fabricated as described in Example 
2 were implanted into a transected tibial nerve of adult male 
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rats. Autograft implants and saline filled nerve conduit 
implants were also tested in comparator/control animals. 
Double immunostaining (axons and Schwarm cells) 
revealed that the implanted nano fiber scaffolds facilitated the 
regeneration of transected tibial nerves across 17 mm nerve 
gaps, and that host derived Schwarm cells infiltrated the 
nanofiber scaffolds from both proximal and distal stumps of 
the nerve. The transected axons entered into the proximal end 
of the nanofiber scaffolds, regenerated through entire length 
of the nano fiber scaffold along the nano fiber films, and moved 10 
into the distal stump of the nerve. This successful regenera-
tion was observed in all nanofiber scaffold treated animals 
(n=12). The regenerating axons always co-localized with the 
aligned Schwarm cells through the entire nanofiber scaffold; 
no regenerated axons were observed without co-localization 15 
with the Schwarm cells. However, aligned Schwarm cell for-
mations without the presence of axons were observed. The 
regenerated axons and the infiltrated Schwarm cells regrew 
along the aligned nano fiber films, suggesting that the aligned 
nano fiber films guide the direction of the regenerated axons 20 
and the infiltrated Schwarm cells after injury akin to the in 
vitro observations ofDRG neurite extension. 
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were observed in axon/Schwarm cell depleted areas, suggest-
ing that Schwarm cells were not the only cells infiltrating into 
the implanted nano fiber scaffolds. Most importantly, the pat-
tern of regenerating axons and the infiltrated Schwarm cells 
were guided by the nanofibers. Overlapping immunostained 
axons with bright field imaged nano fiber films shows that the 
regenerating axons and Schwarm cells grew on or beneath the 
nano fibers. 
Retrograde dye injection into the affected muscle revealed 
that the motoneuron cell bodies in the spinal cord and their 
reformed terminals (i.e., neuromuscular junctions) were ana-
tomically reconnected in nanofiber scaffolds and autograft 
implanted animals, but not in saline filled nerve conduit 
implanted animals. Positive staining of the motoneurons sug-
gests Fluororuby was picked up by the motoneuron terminals, 
diffused through the reinnervated nerve and the implanted 
nanofiber scaffolds and autografts, and accumulated around 
motoneurons in the spinal cord. 
Recordings were taken from mixed, sensory, and motor 
nerve components of the regenerated nerve in response to 
tibial nerve, dorsal root, and ventral root stimulation respec-
tively. In mixed and sensory nerves, significantly higher 
stimulation levels were required to recruit the regenerating 
axons in autograft and nanofiber scaffold implants as com-
pared to normal animals. However, these regenerating axons 
were functional (i.e., propagating an action potential) and it is 
important to note that nanofiber scaffold implants performed 
comparably to autografts. Interestingly, the threshold levels 
of stimulation required to form motor neuron induced com-
In autograft implanted animals, the transected axons 
entered into the autograft nerve and moved into the distal 
stump of nerve. Unlike in the regeneration observed through 25 
nanofiber scaffolds, regenerated axons within the autograft 
treated animals were tightly packed in with the aligned 
Schwarm cells, suggesting that the autografts allowed lesser 
infiltration of non-neuronal cells such as fibroblasts as com-
pared to nanofiber scaffolds. 30 pound action potential (CAP) were found to be similar 
between nanofiber scaffold implants and normal animals (no 
statistical difference). In additional, CAPs recorded from 
autograft and nanofiber scaffold implanted animals were 
broader than those recorded from normal control animals. 
Unlike with nano fiber scaffolds and auto grafts, no cellular 
or extracellular matrix (ECM) structures within the conduit 
was observed in more than 90% of the saline filled nerve 
conduit treated animals. Even though a cable structure 
between proximal and distal nerve stumps was observed in 35 
about 10% of the animals, it was thin (i.e., diameter was 
smaller 50 µm) and stained positive for Collagen type 1, but 
not for NF 160 or S-100. In the 90% of the cases in which the 
nerve conduit was empty, axons were observed only at the 
proximal nerve stump along with the Schwarm cells, but not 
in the distal nerve stump. This observation suggests that the 
saline filled nerve conduits might fail to form the initial fibrin 
cable between proximal and distal nerve stump due to a long 
nerve gap (17 mm gap). 
Immunostaining for Laminin, RECA-1, and GAP-43 
revealed that the infiltrated Schwarm cells reorganized into 
the bands of Bungner along the aligned nanofiber films and 
blood vessels were reformed through the entire length of the 
nano fiber scaffolds. Many small and large blood vessels were 
reformed and, interestingly, some of the blood vessels paral-
leled the direction of the aligned Schwarm cells. Besides 
blood vessel formation, the bands of Bungner consisting of 
aligned Schwarm cells (infiltrated from both proximal and 
distal stump of the nerve) and endogenously deposited lami-
nin were consistently observed. Furthermore, the GAP-43 
and S-100 double immunostaining confirmed that the axons 
observed through entire nano fiber scaffold were regenerating 
or sprouting axons. 
The cross-section of the implants revealed that the pattern 
of nerve regeneration through the nanofiber scaffolds was 
different from that of both auto grafts and of normal controls. 
In the nanofiber scaffolds, the regenerating axons always 
co-localized with infiltrated Schwarm cells, which 
ensheathed the regenerating axons withmyelin through entire 
scaffold. No axons were observed in the absence of Schwarm 
cells. Unlike with autografts and normal controls, however, 
non-neuronal cells including macrophages and fibroblasts 
These results suggest a larger composition of smaller diam-
eter axons, a finding that agrees with the measured distribu-
tion of axon caliber and the extent of myelination. Recovery 
of mixed, sensory, and motoneuron conduction after bridging 
with nanofiber scaffolds or autografts was determined by 
40 measuring the time latency from the application of an elec-
trical pulse at the stimulus site to the detection of the resulting 
CAP at the recording site. Conduction latency in all cases was 
significantly higher across auto grafts and nano fiber scaffolds 
than across normal, unoperated nerves, suggesting that regen-
45 erating nerve propagates action potentials more slowly than 
intact nerve. Comparing autografts and nanofiber scaffolds 
implants, conduction latency across mixed and sensory nerve 
was significantly shorter through autografts. However, in 
motor nerves there was no significant difference in conduc-
50 tion latencies. 
Grid walking studies showed significantly fewer foot slips 
in autograft and nanofiber scaffolds treated animals than in 
saline filled nerve conduit treated animals. These results sug-
gest that both nanofiber scaffolds implants and autografts 
55 result in better functional recovery than saline-filled nerve 
conduit implants. 
In s=ary, the results indicate that a uniaxially oriented 
nanofiber scaffold has an equivalent performance to a mixed 
nerve autograft in 17 mm long nerve gaps without the addi-
60 ti on of exogenous trophic or matrix proteins. When implanted 
across the 17 mm tibial nerve gap, the aligned nanofibers 
enabled Schwarm cell migration and laminin-1 deposition 
along their length, allowing formation of the bands ofBung-
ner through the entire nanofiber scaffold. Tibial nerve regen-
65 eration across the nerve gap was facilitated without the addi-
tion of exogenous proteins or cells, such as neurotrophic 
factors (e.g., nerve growth factor), extracellular matrix mo!-
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ecules (e.g., pre-coatedlaminin), or Schwarm cells. That is, an 
exclusively synthetic scaffold matched the performance of a 
mixed nerve autograft in enabling functional regeneration 
across a long nerve gap. 
EXAMPLE4 
Directional Neurite Extension In Vitro 
A tissue scaffold was constructed which consisted of multi- 10 
layered hydrogel structures embedded with uniaxially ori-
ented electrospun nanofiber monolayers. The nanofibers had 
diameters of 200 to 500 nm and were made of a mixture of 
poly( caprolactone) and poly(lactic-co-glycolic acid). The 
15 hydrogel was a thermo-reversible agarose hydrogel. 
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4. The implantable scaffold of claim 3, wherein the scaf-
fold structure includes a spacer between layers ofuniaxially 
oriented nanofibers in the stacked layers. 
5. The implantable scaffold of claim 4, wherein the spacer 
has a thickness between 50 and 100 µm. 
6. The implantable scaffold of claim 4, wherein the spacer 
comprises a hydro gel, polyethylene glycol, agarose, alginate, 
polyvinyl alcohol, collagen, Matrigel, chitosan, gelatin, or a 
combination thereof. 
7. The implantable scaffold of claim 6, wherein the scaf-
fold comprises alternating layers of oriented nanofibers and 
layers ofhydrogel. 
8. The implantable scaffold of claim 1, wherein the tubular 
conduit comprises a non-biodegradable polymer. 
9. The implantable scaffold of claim 1, wherein the tubular 
conduit comprises a polysulfone. 
Primary rat derived dorsal root ganglia explants were dis-
sected, seeded into one end of the tissue scaffolds, and cul-
tured for four days. After four days of incubation, the scaf-
folds were fixed and cryosectioned for immunohistochemical 
analysis. Neurofilament marker was used to identify axons 
while S-100 was used to identify Schwarm cells. 
10. The implantable scaffold of claim 1, wherein the syn-
thetic polymer of the nanofibers is a synthetic biodegradable 
polymer selected from the group consisting of a poly( capro-
20 lactone ), a poly(lactic-co-glycolic acid), and a combination 
thereof. 
The results demonstrated that the uniaxially oriented neu-
rite outgrowths ofDRG processes were observed through the 
entire scaffold structure. In addition, the oriented neurite 25 
outgrowth was accompanied by aligned Schwarm cells. This 
11. The implantable scaffold of claim 1, wherein the syn-
thetic polymer of the nano fibers is a synthetic non-biodegrad-
able polymer. 
12. The implantable scaffold of claim 11, wherein the 
synthetic non-biodegradable polymer comprises a poly(acry-
lonitrile ). in vitro test demonstrated that (i) uniaxially oriented nanofi-
bers can direct the neurite outgrowth of axons and (ii) multi-
layers of alternating hydrogel and nanofibers can provide 
neurons with a three-dimensional growth environment. 
13. The implantable scaffold of claim 1, wherein the scaf-
fold is an anisotropic three-dimensional structure which pro-
30 vides directional cues to promote cell and tissue growth in the 
Publications cited herein and the materials for which they 
are cited are specifically incorporated by reference. Modifi-
cations and variations of the methods and devices described 
herein will be obvious to those skilled in the art from the 
foregoing detailed description. Such modifications and varia- 35 
tions are intended to come within the scope of the appended 
claims. 
We claim: 
1. An implantable synthetic scaffold for tissue regeneration 40 
comprising: 
a scaffold structure comprising (i) a plurality ofuniaxially 
oriented nanofibers oriented within 20 degrees of the 
uniaxial orientation, the nanofibers consisting essen-
tially of at least one synthetic polymer selected from the 45 
group consisting of poly(hydroxyl acids), poly(lactic) 
acids, polyanhydrides, polyorthoesters, polyamides, 
polyalkylenes, polyalkylene glycols, polyalkylene 
oxides, polyvinyl alcohols, polyvinyl ethers, polyvinyl 
esters, polyvinyl alcohols, poly(butyric acid), polyvi- 50 
nylpyrrolidone, poly(valeric acid), poly(lactide-co-ca-
prolactone ), poly(acrylonitrile), derivatives thereof, 
copolymers thereof, and blends thereof, and (ii) a tubu-
lar conduit consisting essentially of a synthetic polymer, 
the nanofibers being disposed within an annular channel 55 
defined by and within the tubular conduit, 
wherein the scaffold structure is effective to guide cell 
migration in vitro or in vivo without requiring exog-
enous trophic or extracellular matrix factors. 
2. The implantable scaffold of claim 1, wherein the nanofi- 60 
bers have a diameter between about 400 nm and about 800 
nm. 
3. The implantable scaffold of claim 1, wherein the scaf-
fold structure comprises two or more stacked layers of uniaxi-
ally oriented nanofibers, the layers being oriented such that 65 
the nanofiber orientation among the layers is substantially 
identical. 
structure. 
14. The implantable scaffold of claim 13, wherein the 
anisotropic three-dimensional structure is effective to guide 
the ingrowth of cells into the structure. 
15. The implantable scaffold of claim 14, wherein the 
three-dimensional structure is effective to guide the ingrowth 
of Schwarm cells. 
16. The implantable scaffold of claim 13, wherein the 
anisotropic three-dimensional structure is effective to guide 
the direction of axon regeneration and the infiltration of 
Schwarm cells; and 
wherein the tubular conduit in which the anisotropic three-
dimensional structure is disposed is suited for placement 
between two nerve stumps. 
17. A scaffold for tissue regeneration comprising: 
at least two layers which consist essentially of a plurality of 
uniaxially oriented, polymeric nanofibers, wherein at 
least 75% of the nanofibers are oriented within 20 
degrees of the uniaxial orientation and wherein the lay-
ers are stacked and oriented such that the nanofiber 
orientation of the layers is substantially identical; 
one or more spacers disposed between the at least two 
layers ofuniaxially oriented nanofibers, 
wherein the polymeric nano fibers are made of a synthetic 
polymer selected from the group consisting of poly(hy-
droxyl acids), poly(lactic) acids, polyanhydrides, poly-
orthoesters, polyamides, polyalkylenes, polyalkylene 
glycols, polyalkylene oxides, polyvinyl alcohols, poly-
vinyl ethers, polyvinyl esters, polyvinyl alcohols, poly 
(butyric acid), polyvinylpyrrolidone, poly(valeric acid), 
poly(lactide-co-caprolactone ), poly( acrylonitrile ), 
derivatives thereof, copolymers thereof, and blends 
thereof, and 
wherein the at least two layers of uniaxially oriented 
nanofibers are effective to guide cell migration in vitro 
or in vivo without requiring exogenous trophic or extra-
cellular matrix factors. 
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18. The scaffold of claim 17, wherein the one or more 
spacers comprise a hydrogel, polyethylene glycol, agarose, 
alginate, polyvinyl alcohol, collagen, Matrigel, gelatin, or a 
combination thereof. 
19. A method for fabricating an implantable scaffold for 
tissue regeneration, the method comprising the steps of: 
electrospinning at least one synthetic polymer to form two 
or more films of uniaxially oriented nano fibers, wherein 
the nanofiber films consist essentially ofuniaxially ori-
ented synthetic nanofibers and the at least one synthetic 
10 polymer is selected from the group consisting of poly 
(hydroxyl acids), poly(lactic) acids, polyanhydrides, 
polyorthoesters, polyamides, polyalkylenes, polyalky-
lene glycols, polyalkylene oxides, polyvinyl alcohols, 
polyvinyl ethers, polyvinyl esters, polyvinyl alcohols, 
poly(butyric acid), polyvinylpyrrolidone, poly(valeric 15 
acid), poly(lactide-co-caprolactone ), poly(acryloni-
trile ), derivatives thereof, copolymers thereof, and 
blends thereof; and 
stacking the two or more uniaxially oriented nanofiber 
films together to form a three-dimensional scaffold; and 20 
disposing the oriented, three-dimensional scaffold inside a 
tubular conduit with the nanofiber orientation of the 
nanofiber films being substantially aligned in the direc-
tion of the axis of the conduit, 
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wherein the scaffold is effective to guide cell migration in 
vitro or in vivo without requiring exogenous trophic or 
extracellular matrix factors. 
20. The method of claim 19, further comprising interpos-
ing layers of at least on hydrogel in between the films of 
uniaxially oriented nanofibers. 
21. A method of tissue regeneration comprising: 
implanting into a patient the implantable scaffold of claim 
1 at a site in need of tissue regeneration. 
22. The method of claim 21, wherein the site is between 
two ends of a nerve in need of regeneration. 
23. A method for regenerating nerve tissue in a mammal, 
comprising: 
implanting in a mammal the implantable scaffold of claim 
16, in a gap between two stump ends of a transected 
nerve in the mammal; 
securing a first end of the tubular conduit about one of the 
nerve stumps; and 
securing an opposed second end of the tubular conduit 
about the second nerve stump; and 
allowing axons from the nerve stumps to regenerate and 
Schwami cells to infiltrate into the tubular conduit. 
* * * * * 
